Compare Invesco WilderHill Clean Energy ETF (PBW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $28.29 (market cap $335.90M), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 226.7× Invesco WilderHill Clean Energy ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Invesco WilderHill Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 46 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PBW | REGN | |
|---|---|---|
Market Cap | $335.90M | $76.14B |
Volume | 628,890 | 500,239 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $852.03 |
52-Week Low | $28.29 | $557.73 |
Typical Hold Time | 46 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW, the Invesco WilderHill Clean Energy ETF, trades at $28.92, down 2.89% today amid a bearish technical signal from moving averages. The ETF's unique selection criteria prioritize ecological factors over financial metrics, resulting in concentrated exposure to the clean energy sector. Recent institutional selling, including a 96.3% reduction by IFP Advisors Inc. in Q2 2026 (SEC filing, September 18, 2026), reflects cautious sentiment despite long-term growth drivers like energy security and data center demand.
Outlook remains challenged by near-term volatility and sector underperformance versus broad markets, though global investment in clean energy offers structural tailwinds. Key risks include oil price swings, Fed policy impacts, and lack of diversification. Investors face a trade-off between speculative growth potential and elevated sensitivity to macroeconomic shifts.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
